Ever Supreme Bio Technology (長聖) announced yesterday (April 1) that its consolidated revenue for March reached 66.24 million NTD, a 20% year-on-year increase, setting a new record for the same period in previous years. The company’s consolidated revenue for the first quarter of this year totaled 189 million NTD, reflecting a 15.2% year-on-year growth. The growth momentum primarily came from the significantly improved market acceptance of cell therapy products, which further boosted the rapid expansion of the cell contract development and manufacturing (CDMO) business.
Wen-Liang Huang, the CEO of Ever Supreme, stated that the company's order visibility extends to the first quarter of 2026, and the number of collaborating hospitals and cell therapy projects continues to expand. The company maintains an optimistic outlook for the year and expects to achieve record-breaking performance in 2025.
In the field of regenerative medicine, Ever Supreme continues to advance the clinical development of its allogeneic umbilical mesenchymal stem cells (UMSC01) therapy. The treatment for acute myocardial infarction has entered Phase IIa clinical trials. This phase uses a control group design and assesses improvements in heart and lung function through cardiopulmonary exercise testing (CPET). Preliminary results show that patients who received stem cell treatment experienced significant improvements in overall heart and lung function within six to twelve months after the injection, with no serious adverse reactions. All participants were discharged successfully.
Additionally, a 75-year-old patient, Mr. Wu, who participated in the Phase I clinical trial of UMSC01, recently attended an Ever Supreme event and shared his experience. Nearly five years after receiving UMSC01 stem cell therapy in 2020, he has maintained normal heart ultrasound function during follow-up visits. He can still engage in everyday activities such as hiking in Xitou, demonstrating the potential long-term benefits of stem cell therapy for cardiac repair.
According to medical literature, about 50% of acute myocardial infarction patients are at risk of developing heart failure. Stem cell therapy offers a new possibility for repairing damaged heart tissue, opening a new chapter in the treatment of critical illnesses. Analysts believe that if UMSC01 demonstrates preliminary efficacy and safety during the Phase II clinical trial, it is likely to enter the medical market through the Regenerative Medicine Pharmaceutical Regulations and obtain a five-year temporary drug license. This would expedite its market entry and significantly enhance the product's commercial value.
Wen-Liang Huang emphasized that the company is dedicated to developing innovative treatments for critically ill and life-threatening patients, spanning four core areas: immune cell therapy, stem cell therapy, nanoparticle pharmaceutical platforms, and exosome technology platforms.
Resource: 長聖營收 寫最強3月
